China
Africa
Explore chapters and articles related to this topic
Introduction
Published in Arwa Ahmed Gasm Elseid, Alnazier Osman Mohammed Hamza, Computer-Aided Glaucoma Diagnosis System, 2020
Arwa Ahmed Gasm Elseid, Alnazier Osman Mohammed Hamza
Glaucoma is one of the most common causes of permanent blindness worldwide. Nonetheless, if glaucoma is diagnosed early enough, it can be properly managed to prevent a major loss of vision; although there is no cure for glaucoma, medication can be used to prevent vision loss (Lim et al., 2012). Following are six tests used to help detect glaucoma mentioned at www.biomedical-engineering-online.com.
Intravitreal triamcinolone acetonide in macular edema
Published in A Peyman MD Gholam, A Meffert MD Stephen, D Conway MD FACS Mandi, Chiasson Trisha, Vitreoretinal Surgical Techniques, 2019
safety of a single intravitreal injection of triamcinolone acetonide (4 mg) was evaluated in patients with subfoveal choroidal neovascularization caused by ARMD. Of 75 eyes assigned to study treatment and 76 eyes assigned to placebo, there were no moderate or severe adverse events related to the surgical procedure in either group. Triamcinolone acetonide-treated eyes had a significantly increased risk of developing mild or moderate elevation of IOP. Topical glaucoma medication reduced the IOP to acceptable levels in all patients. There was significant progression of cataract in the triamcinolone acetonide-treated eyes. Gillies et al141 concluded that despite a significant adverse event profile, intravitreal triamcinolone acetonide is generally well tolerated by the human eye as long as patients are carefully followed up by their surgeon and treated appropriately.
Eyedrops use perception during fasting
Published in Elida Zairina, Junaidi Khotib, Chrismawan Ardianto, Syed Azhar Syed Sulaiman, Charles D. Sands, Timothy E. Welty, Unity in Diversity and the Standardisation of Clinical Pharmacy Services, 2017
B.S. Zulkarnain, Sumarno, Y. Nita, R. Loebis
Furthermore, there was no significant difference for the perception of using eyedrops for emergency, unpleasant or critical situations such as painful eye and conditions that affect the eye between healthcare providers and non healthcare providers. They were more likely to continue their medication with those above situations. even though they are fasting. While this is true, it should be considered regarding asymptomatic disease that has long term consequences such as glaucoma. Primary open angle glaucoma is a chronic disease that does not cause pain or reduced vision in the short term. Glaucoma treatment needs compliance with medication. If glaucoma medication is not used because there are no symptoms of painful eye or reduced vision, this would have a long-term effect, especially if Muslims omit the treatment for one month every year (Tsai 2006, Kumar & Jivan 2007).
Corneal epithelium and limbal region alterations due to glaucoma medications evaluated by anterior segment optic coherence tomography: a case-control study
Published in Cutaneous and Ocular Toxicology, 2021
Hande Güçlü, Ayça Küpeli Çınar, Abdülkadir Can Çınar, İrfan Akaray, Merve Şambel Aykutlu, Ahmet Kürşad Sakallıoğlu, Vuslat Gürlü
A total of 95 subjects were included: 47 eyes of 47 patients with glaucoma medication and 48 eyes of 48 healthy subjects. The mean age of the patients and controls was 63.6 ± 7.2 years and 63.6 ± 7.3 years respectively. There was no significant difference between The age (p = 0.7) and gender (p = 0.5) between the patients and controls. Of the 47 patients using glaucoma medication, 9 (19%) were in Group 1, 20 (42%) were in Group 2, 13 (27%) were in Group 3 and 5 (10%) were in Group 4. The purpose of this grouping was to determine the total medication burden of the patients. The mean duration of glaucoma treatment was 82.8 ± 49.3 months. Group 1 used the anti-glaucoma drugs for 61.3 ± 15.1 months, Group 2 used the anti-glaucoma drugs for 88.8 ± 60.2 months, Group 3 used the anti-glaucoma drugs for 81.2 ± 53.6 months, Group 4 used the anti-glaucoma drugs for 101.8 ± 7.3 months.
Assessment of medication therapy adherence in glaucoma: scoping review
Published in Expert Review of Ophthalmology, 2021
Amalia Mihaela Rosu, André Coelho, Pedro Camacho
Eye drops administration aids were suggested as a strategy to overcome the barrier to medication adherence, some of which are already commercially available[32]. Eye drops administration technique was evaluated[31,32,37,47] and the difficulty in self-administration of eye drops was, in several studies, associated with low adherence to glaucoma therapy[29,37,45]. The study conducted by Hermann et al [36] showed that, on average, 20% of glaucoma medication was wasted due to inefficient administration, using more than one drop per dose. The teaching by health care personnel on how to administer the eye drops was positively associated with adherence[30]. In the article by Djafari et al [31]. the ability to instill eye drops did not correlate with medication adherence. The same was verified by Rajurkar et al [47]., where 35,76% of the participants demonstrated inadequate eye drops administration technique.
Five-Year Outcomes Prospective Study of Two First-Generation Trabecular Micro-Bypass Stents (iStent®) in Open-Angle Glaucoma
Published in Current Eye Research, 2021
Hady Saheb, Eric D. Donnenfeld, Kerry D. Solomon, Lilit Voskanyan, David F. Chang, Thomas W. Samuelson, Iqbal Ike K Ahmed, L Jay Katz
In addition to IOP reduction, patients in the present study eliminated 1 glaucoma medication from their preoperative regimen. Medication adherence is widely known to be low, and medications can be associated with local and systemic side effects, ocular surface toxicities, complex dosing regimens, financial costs, and difficulty with instillation.5–12 An inherent advantage of surgical glaucoma treatments is that their effectiveness is not limited by medication side effects or suboptimal adherence. In addition, the IOP-reducing ability of 2-iStent implantation did not diminish over five years of follow-up in this study, contrasting with the incidence of repeat treatments seen with SLT,13 and the waning IOP-reducing effect of cataract extraction over time.44–46